Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein Occlusion

Al-Azhar University

Status: Completed

Conditions: Branch Retinal Vein Occlusion

Treatments: Drug: aflibercept (2mg/0.05ml)

Study type: Interventional

Funder types: Other

Identifiers

NCT06146309

Unilateral Branch Retinal Vein

Details and patient eligibility

About

Several studies have indicated a relation between the development of RVO and elevated intraocular pressure (IOP) and glaucoma [9]. Further investigations into the structural alterations in the fellow eyes of individuals with unilateral RVO have revealed that the pRNFL is thinner than in healthy eyes, suggesting that there may be systemic risk factors for both RVO and glaucoma

Enrollment: 60 patients

Sex: All

Ages: 47 to 68 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• patients with unilateral BRVO

Exclusion criteria

• History of retinal and/or optic nerve diseases involving glaucomatous optic disc, ischemic optic neuropathy, or optic neuritis.
• History of trauma, intravitreal injections, vitreoretinal surgeries, and retinal or macular lasers.
• A significant media opacity that makes it difficult to capture clear images.
• No history of diabetes and/or hypertension in those recruited as the control group

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

Patients with unilateral BRVO

Experimental group

Treatment:

Drug: aflibercept (2mg/0.05ml)

Healthy individuals

No Intervention group